Bisphenol-A disruption of the endocrine pancreas and blood glucose homeostasis

The link between endocrine disruptors and altered blood glucose homeostasis has been recently suggested. Epidemiological studies have correlated levels of phthalates, dioxins and persistent organic pollutants with alterations of blood glucose homeostasis in humans. Environmentally relevant doses of...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of andrology Vol. 31; no. 2; pp. 194 - 200
Main Authors Ropero, A.B, Alonso-Magdalena, P, García-García, E, Ripoll, C, Fuentes, E, Nadal, A
Format Journal Article
LanguageEnglish
Published Oxford, UK Oxford, UK : Blackwell Publishing Ltd 01.04.2008
Blackwell Publishing Ltd
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The link between endocrine disruptors and altered blood glucose homeostasis has been recently suggested. Epidemiological studies have correlated levels of phthalates, dioxins and persistent organic pollutants with alterations of blood glucose homeostasis in humans. Environmentally relevant doses of the ubiquitous endocrine disruptor bisphenol-A (BPA) have profound effects on mice endocrine pancreas - an essential tissue involved in glucose metabolism. BPA exerts rapid non-genomic effects on insulin releasing β-cells and glucagon releasing α-cells within freshly isolated islets of Langerhans. In vivo, a single BPA injection of 10μg/kg rapidly increases plasma insulin and concomitantly decreases glycaemia. When mice were treated with BPA 100μg/kg/day for 4 days, the environmental oestrogen produced an increase in β-cell insulin content along with a post-prandial hyperinsulinaemia and insulin resistance. The results reviewed here demonstrate that doses well below the current lowest observed adverse effect level considered by the US-EPA, disrupt pancreatic β-cell function producing insulin resistance in male mice. Therefore, this altered blood glucose homeostasis by BPA exposure may enhance the risk of developing type II diabetes.
Bibliography:http://dx.doi.org/10.1111/j.1365-2605.2007.00832.x
ark:/67375/WNG-NR90WC1D-7
ArticleID:IJAN832
istex:6C64204ABC2EAD131234D1877CA1BAB82F44F38F
ISSN:0105-6263
1365-2605
DOI:10.1111/j.1365-2605.2007.00832.x